Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.66 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.66 |
| ▸ | RAB9A | P51151 | 2/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.65 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18887582 | 0.94 | ALDH1A1 (0.59) | ALDH1A1HSD17B10CYP1A2RAB9APOLB | |
| SCHEMBL1901172 | 0.91 | ALDH1A1 (0.76) | ALDH1A1HSD17B10CYP1A2RAB9APOLB | |
| SCHEMBL14338254 | 0.84 | MTNR1B (0.61) | ALDH1A1HSD17B10CYP1A2RAB9ATP53 | |
| SCHEMBL18814669 | 0.84 | ALDH1A1 (0.65) | ALDH1A1HSD17B10CYP1A2RAB9APOLB | |
| SCHEMBL697192 | 0.83 | GPR35 (0.55) | ALDH1A1HSD17B10CYP1A2RAB9APOLB | |
| SCHEMBL4714652 | 0.83 | HSD17B10 (0.71) | ALDH1A1HSD17B10CYP1A2RAB9APOLB | |
| SCHEMBL23576901 | 0.82 | HTT (0.63) | ALDH1A1HSD17B10RAB9APOLBL3MBTL1 | |
| SCHEMBL21310282 | 0.82 | ALDH1A1 (0.63) | ALDH1A1HSD17B10CYP1A2RAB9APOLB | |
| SCHEMBL1487963 | 0.82 | ALDH1A1 (0.63) | ALDH1A1HSD17B10CYP1A2RAB9APOLB | |
| SCHEMBL16488795 | 0.82 | MEN1 (0.51) | ALDH1A1HSD17B10POLBTP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11597699-B2 | MEK inhibitors and methods of their use | EXELIXIS, INC. (US) | 2023-03-07 | — | — | US | disclosed |
| CN-109053523-B | Azetidines as MEK inhibitors for the treatment of proliferative diseases | 埃克塞利希斯股份有限公司 | 2022-03-25 | — | — | CN | disclosed |
| US-20200339596-A1 | FUROXAN-BASED COMPOUNDS AND USES THEREOF | UNIVERSITY OF MASSACHUSETTS | 2020-10-29 | — | — | US | disclosed |
| CN-111643496-A | Methods of using MEK inhibitors | 埃克塞利希斯股份有限公司 | 2020-09-11 | — | — | CN | disclosed |
| US-20200283383-A1 | MEK Inhibitors and Methods of Their Use | EXELIXIS, INC. | 2020-09-10 | — | — | US | disclosed |
| US-20200031770-A1 | MEK INHIBITORS AND METHODS OF THEIR USE | EXELIXIS, INC. | 2020-01-30 | — | — | US | disclosed |
| CN-110668988-A | Azetidines as MEK inhibitors for the treatment of proliferative diseases | 埃克塞利希斯股份有限公司 | 2020-01-10 | — | — | CN | disclosed |
| EP-3180326-B1 | BENZODIAZEPINE DERIVATIVES AS CCK2/GASTRIN RECEPTOR ANTAGONISTS | TRIO MEDICINES LTD (GB) | 2019-10-23 | — | — | EP | disclosed |
| US-20190144382-A1 | MEK Inhibitors and Methods of Their Use | EXELIXIS, INC. | 2019-05-16 | — | — | US | disclosed |
| EP-2101759-B1 | METHODS OF USING MEK INHIBITORS | EXELIXIS INC (US) | 2018-10-10 | — | — | EP | disclosed |
| US-7173032-B2 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2007-02-06 | — | — | US | disclosed |
| US-7173032-B2 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2007-02-06 | — | — | US | disclosed |
| WO-2007002441-A1 | METHODS OF USE FOR NON-ATP COMPETITIVE TYROSINE KINASE INHIBITORS TO TREAT PATHOGENIC INFECTION | EMORY UNIVERSITY (US) | 2007-01-04 | — | — | WO | disclosed |
| CN-1805923-A | Benzamide derivative or salt thereof | ASTELLAS PHARMA INC (JP) | 2006-07-19 | — | — | CN | disclosed |
| EP-1632477-A1 | BENZAMIDE DERIVATIVE OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2006-03-08 | — | — | EP | disclosed |
| WO-2004103998-A1 | QUINOLINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-12-02 | — | — | WO | disclosed |
| US-5512663-A | Disazo reactive dyestuffs | BAYER AKTIENGESELLSCHAFT (DE) | 1996-04-30 | — | — | US | disclosed |
| EP-0474039-B1 | Ortho-aminoazo compounds | BAYER AG (DE) | 1994-11-09 | — | — | EP | disclosed |
| US-5183881-A | Chemical intermediate for metallized dyes | BAYER AKTIENGESELLSCHAFT (DE) | 1993-02-02 | — | — | US | disclosed |
| EP-0474039-A1 | Ortho-aminoazo compounds | BAYER AG (DE) | 1992-03-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200283383-A1 | MEK Inhibitors and Methods of Their Use | BRAF, NRAS, MAP3K20 | ALDH1A1 1234/4885HSD17B10 1885/4885CYP1A2 1175/4885 |
| US-20200339596-A1 | FUROXAN-BASED COMPOUNDS AND USES THEREOF | PARK7, HTT, PRDX5 | ALDH1A1 1029/4885HSD17B10 361/4885CYP1A2 545/4885 |
| US-20190144382-A1 | MEK Inhibitors and Methods of Their Use | BRAF, NRAS, MAP3K20 | ALDH1A1 1234/4885HSD17B10 1885/4885CYP1A2 1175/4885 |
| US-11597699-B2 | MEK inhibitors and methods of their use | BRAF, NRAS, MAP3K20 | ALDH1A1 1234/4885HSD17B10 1885/4885CYP1A2 1175/4885 |
| US-20200031770-A1 | MEK INHIBITORS AND METHODS OF THEIR USE | BRAF, NRAS, MAP3K20 | ALDH1A1 1234/4885HSD17B10 1885/4885CYP1A2 1175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.